Crystalline Tryptamine Salts for Accurate API Molecular Weight
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing drug development lacks the characterization of crystalline forms of active pharmaceutical ingredients (APIs) such as tryptamines, leading to inaccuracies in molecular weight calculations and potential errors in dosing, potency, and toxicity assessments.
Innovation Solution
Characterization and development of crystalline forms of serotonin hydrochloride hydrate, 4-AcO-EPT fumarate fumaric acid, MPT iodide, and EPT fumarate, with specific X-ray powder diffraction patterns and space groups, to provide stable and well-defined APIs for pharmaceutical compositions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If amorphous forms of APIs are used, then ease of manufacture is improved, but measurement precision and manufacturing precision deteriorate due to inaccurate molecular weight calculations
Solution Approach 1:
The patent changes the physical state parameter of the API from amorphous to crystalline form. This transformation enables accurate determination of molecular weight through crystal structure analysis, resolving the measurement precision issue while maintaining manufacturability through established crystallization techniques
Solution Approach 2:
The patent replaces indirect molecular weight estimation methods (suitable for amorphous forms) with direct crystal structure determination using X-ray diffraction. This substitution provides accurate molecular weight data for dosing calculations without compromising manufacturing ease
2Manufacturing precision
If crystalline forms of APIs are developed, then measurement precision and manufacturing precision are improved, but device complexity and process difficulty increase
Solution Approach 1:
The patent uses X-ray powder diffraction patterns as fingerprints to identify and characterize crystalline forms. This copying approach allows rapid identification of crystal structures without requiring complex single-crystal growth and analysis, reducing the overall complexity of crystal characterization
Solution Approach 2:
The patent establishes a universal methodology for crystalline API characterization that can be applied across different tryptamine compounds. The same crystallization and XRPD analysis approach works for multiple APIs, reducing the need for compound-specific complex procedures
3Reliability
If crystalline forms are characterized, then reliability of dosing and potency assessments is improved, but loss of time in characterization processes increases
Solution Approach 1:
The patent performs preliminary crystallization and XRPD characterization during the early drug development stages. This preliminary action establishes the correct crystal structure and molecular weight data before clinical trials begin, ensuring reliable dosing throughout the development process without time loss during later stages
Solution Approach 2:
The patent focuses characterization efforts on the specific crystalline form that will be used in the final drug product. By identifying and characterizing only the relevant polymorph, the process avoids unnecessary time spent on characterizing alternative crystal forms that will not be used
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The crystalline forms enhance the chemical and physical properties of APIs, ensuring accurate molecular weight determination and reducing errors in drug formulations, thereby improving therapeutic efficacy and safety.
Implementation Method 1
an X-ray powder diffraction (XRPD) pattern substantially similar to FIG. 3; and an X-ray powder diffraction pattern characterized by peaks at 11.1, 20.6, and 26.5°2θ±0.2°2θ
Implementation Method 2
an X-ray powder diffraction (XRPD) pattern substantially similar to FIG. 3; and an X-ray powder diffraction pattern characterized by peaks at 11.1, 20.6, and 26.5°2θ±0.2°2θ
Data Source
AI summary
The disclosure relates to 2-(5-hydroxy-1H-indol-3-yl)ethan-1-aminium hydrate chloride (5-HT hydrochloride hydrate) and its crystalline form 1, and to pharmaceutical compositions containing 5-HT hydrochloride hydrate or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to crystalline form 1 of (2E)-but-2-enedioic acid bis({2-[4-(acetyloxy)-1H-indol-3-yl]ethyl}(ethyl)propylazanium) (2E)-but-2-enedioate (4-AcO-EPT fumarate fumaric acid), and to pharmaceutical compositions containing crystalline form 1 of 4-AcO-EPT fumarate fumaric acid and to methods of treatment using it. The disclosure further relates to [2-(1H-indol-3-yl)ethyl](methyl)propylazanium iodide (MPT iodide) and its crystalline form 1, and to pharmaceutical compositions containing MPT iodide or its crystalline form 1 and to methods of treatment using them. The disclosure further relates to bis(ethyl[2-(1H-indol-3-yl)ethyl]propylazanium) (2E)-but-2-enedioate (EPT fumarate) and its crystalline form 1, and to pharmaceutical compositions containing EPT fumarate or its crystalline form 1 and to methods of treatment using them. EPT fumarate is a novel compound and crystalline form.